Publicacións en colaboración con investigadores/as de University of Washington School of Medicine (18)

2024

  1. The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection: 2024 Update

    Surgical Infections, Vol. 25, Núm. 6, pp. 419-435

2023

  1. Erratum: Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (Nature communications (2021) 12 1 (3417))

    Nature communications

2022

  1. New insights into the genetic etiology of Alzheimer's disease and related dementias

    Nature genetics, Vol. 54, Núm. 4, pp. 412-436

  2. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)

    Nature

  3. Stroke genetics informs drug discovery and risk prediction across ancestries

    Nature, Vol. 611, Núm. 7934, pp. 115-123

2021

  1. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Nature communications, Vol. 12, Núm. 1, pp. 3417

2020

  1. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

    ACR Open Rheumatology, Vol. 2, Núm. 8, pp. 459-470

2019

  1. Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2)

    Nature Genetics

  2. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing

    Nature Genetics, Vol. 51, Núm. 3, pp. 414-430

  3. Novel common genetic susceptibility loci for colorectal cancer

    Journal of the National Cancer Institute, Vol. 111, Núm. 2, pp. 146-157

2018

  1. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: A pooled analysis of the PALACE 1-3 studies

    RMD Open, Vol. 4, Núm. 1

2016

  1. Genetic influences on schizophrenia and subcortical brain volumes: Large-scale proof of concept

    Nature Neuroscience, Vol. 19, Núm. 3, pp. 420-431

2015

  1. Ghrelin

    Molecular Metabolism, Vol. 4, Núm. 6, pp. 437-460

  2. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis

    Journal of Rheumatology, Vol. 42, Núm. 3, pp. 479-488

2014

  1. Molecular epidemiology and virulence of Escherichia coli O16: H5-ST131: Comparison with H30 and H30-Rx subclones of O25b: H4-ST131

    International Journal of Medical Microbiology, Vol. 304, Núm. 8, pp. 1247-1257

  2. Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: A systematic review and meta-analysis

    Journal of Neuroimmunology, Vol. 274, Núm. 1-2, pp. 215-224

  3. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 6, pp. 1020-1026

2001

  1. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: A meta-analysis of randomised controlled trials

    Drug Safety, Vol. 24, Núm. 11, pp. 863-868